Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...

By analysing MRI scans and a simple blood test from hundreds of patients, researchers identified patterns that reveal how ...

The FDA has rejected Sanofi's application seeking approval of tolebrutinib to treat certain forms of MS in its present form.

Fernando Mendoza prominently mentioned his mother in his Heisman Trophy acceptance speech. Here's what you should know about ...

People typically develop multiple sclerosis between ages 20 and 40, but late-onset MS affects those 50 years and older. Your doctor can best diagnose and advise on possible treatments, such as ...

Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...

Sanofi (SNY) stock is in focus as the company agrees to acquire Dynavax Technologies (DVAX) and the FDA rejects its multiple ...